Active, not recruitingPhase 2NCT05167721
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy
Studying Multiple system atrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Wolfgang Singer, MDMayo Clinic
- Intervention
- Autologous Mesenchymal Stem Cells(biological)
- Enrollment
- 71 target
- Eligibility
- 30-70 years · All sexes
- Timeline
- 2021 – 2026
Study locations (1)
- Mayo Clinic, Rochester, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05167721 on ClinicalTrials.govOther trials for Multiple system atrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07446894MSA-01 in Multiple System AtrophyTokyo University
- RECRUITINGPHASE2NCT07197866An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System AtrophyTeva Branded Pharmaceutical Products R&D LLC
- ENROLLING BY INVITATIONNCT07081841AB-1005 Long-Term Follow-up StudyAskBio Inc
- RECRUITINGPHASE1, PHASE2NCT06831500Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.Julien Bally
- RECRUITINGEARLY PHASE1NCT06765733The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System AtrophyBeijing Tiantan Hospital
- RECRUITINGPHASE2NCT06868628A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)Tiziana Life Sciences LTD
- RECRUITINGNCT07353463Shanghai Clinical Cohort - Parkinson's Disease (Reserve)Ruijin Hospital
- RECRUITINGEARLY PHASE1NCT06891703[18F]ACI-15916 PET in α-synucleinopathiesAC Immune SA